Mannitol

Generic Name: Mannitol

Brand Names: Aridol, Bronchitol, Cystosol, Osmitrol, Sag-M

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₄O_₆

CAS Number: 69-65-8

Unique Ingredient Identifier: 3OWL53L36A

Background: Mannitol is an osmotic diuretic that is metabolically inert in humans and occurs naturally, as a sugar or sugar alcohol, in fruits and vegetables. Mannitol elevates blood plasma osmolality, resulting in enhanced flow of water from tissues, including the brain and cerebrospinal fluid, into interstitial fluid and plasma. As a result, cerebral edema, elevated i...

Indication: Used for the promotion of diuresis before irreversible renal failure becomes established, the reduction of intracranial pressure, the treatment of cerebral edema, and the promotion of urinary excretion of toxic substances.
...

Associated Conditions: Acute Renal Failure (ARF), Cystic Fibrosis (CF), Edema of the cerebrum, Increased Intra Ocular Pressure (IOP)

Associated Therapies: Bladder irrigation therapy

Clinical Trials

A Study to Select the Dose and Evaluate the Effectiveness and Safety of the Drug Refralon®, Tablets, 1 mg for Long-term Use to Prevent Recurrence of Atrial Fibrillation/Flutter After Terminating Its Persistent Form

Phase 2

Recruiting

Conditions: Atrial Fibrillation
Atrial Flutter

Interventions: Drug: 4-Nitro-N-[(1RS)-1-(4-fluorophenyl)-2-(1-ethylpiperidin-4-yl)ethyl]benzamide hydrochloride
Drug: Mannitol

First Posted Date: 2024-08-06

Last Posted Date: 2024-08-22

Lead Sponsor: National Medical Research Center for Cardiology, Ministry of Health of Russian Federation

Target Recruit Count: 200

Registration Number: NCT06540352

Locations: 🇷🇺
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation Organization, Moscow, Russian Federation

Effect of Mannitol on Recovery Pattern After Orthognathic Surgery

Not Applicable

Active, not recruiting

Conditions: Orthognathic Surgery

Interventions: Drug: Ringer's Lactate
Drug: Mannitol

First Posted Date: 2024-05-06

Last Posted Date: 2024-07-23

Lead Sponsor: National Cancer Institute, Egypt

Target Recruit Count: 60

Registration Number: NCT06400355

Locations: 🇪🇬
Benha Univesity, Cairo, Egypt

U-LABA/ICS Effects on Exercise Performance, Formoterol

Not Applicable

Completed

Conditions: Exercise Performance

Interventions: Drug: Formoterol
Drug: Placebo
Drug: Symbicort
Drug: Mannitol

First Posted Date: 2023-10-30

Last Posted Date: 2024-08-13

Lead Sponsor: Morten Hostrup, PhD

Target Recruit Count: 20

Registration Number: NCT06105671

Locations: 🇩🇰
August Krogh Building, Copenhagen, Denmark

Dose-finding PKPD Trial for RE02 in Healthy Subjects

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: Manitol
Drug: RE02

First Posted Date: 2023-08-07

Last Posted Date: 2024-11-27

Lead Sponsor: Reconnect Labs

Target Recruit Count: 4

Registration Number: NCT05979727

Locations: 🇨🇭
University Hospital of Psychiatry Zurich, Zürich, ZH, Switzerland

Effectiveness of Mannitol Versus Polyethylene Glycol Electrolyte Dispersion as a Salve for Patients With Inadequate Bowel Preparation: a Randomized Controlled Clinical Trial

Not Applicable

Recruiting

Conditions: Bowel Cleansing; Good Taste

Interventions: Drug: Polyethylene glycol electrolyte
Drug: Mannitol

First Posted Date: 2023-06-22

Last Posted Date: 2023-06-22

Lead Sponsor: Ningbo No. 1 Hospital

Target Recruit Count: 134

Registration Number: NCT05912114

Locations: 🇨🇳
Ningbo first hospital, Ningbo, Zhejiang, China

Assessment of the Efficacy of Calcium Dobesilate vs. Placebo on SARS-CoV-2 Viral Load Amongst Outpatients With COVID-19.

Phase 2

Completed

Conditions: COVID-19 Virus Disease

Interventions: Drug: Mannitol
Drug: Calcium Dobesilate

First Posted Date: 2022-03-31

Last Posted Date: 2024-02-28

Lead Sponsor: Hervé SPECHBACH

Target Recruit Count: 74

Registration Number: NCT05305508

Locations: 🇨🇭
Division and Department of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland

Effect of Mannitol on Postreperfusion Syndrome During Living Donor Liver Transplant

Early Phase 1

Completed

Conditions: Liver Transplant Disorder

Interventions: Other: 0.9% normal saline
Drug: Mannitol

First Posted Date: 2022-03-14

Last Posted Date: 2023-01-18

Lead Sponsor: Ain Shams University

Target Recruit Count: 60

Registration Number: NCT05277623

Locations: 🇪🇬
Medicine Ain Shams University, Cairo, Egypt

A Study of Two Formulations (Both Refrigerated and Room Temperature) Using an Autoinjector Device in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Sodium chloride
Drug: Citrate buffer
Drug: Mannitol
Device: Prefilled Autoinjector

First Posted Date: 2021-12-13

Last Posted Date: 2022-01-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 44

Registration Number: NCT05154968

Locations: 🇨🇦
Syneos Health, Québec, Canada

Retrograde Autologous Priming and Mannitol for Reducing Hemodilution in Cardiac Surgery

Phase 3

Withdrawn

Conditions: Coronary Artery Disease
Fluid Overload
Hemodilution

Interventions: Procedure: Retrograde autologous priming
Drug: Mannitol
Procedure: Conventional Priming

First Posted Date: 2021-05-03

Last Posted Date: 2023-02-28

Lead Sponsor: Hamilton Health Sciences Corporation

Registration Number: NCT04870073

Locations: 🇨🇦
Hamilton General Hospital, Hamilton, Ontario, Canada

Mannitol Use During Cadaveric Kidney Transplantation

Not Applicable

Conditions: Renal Dialysis

Interventions: Drug: Saline
Drug: Mannitol

First Posted Date: 2021-01-12

Last Posted Date: 2021-01-22

Lead Sponsor: Rabin Medical Center

Target Recruit Count: 32

Registration Number: NCT04705402

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy